Indee Labs

Indee Labs identified intracellular delivery as the critical bottleneck in T cell immunotherapy manufacturing. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Researchers and biotech companies developing CAR-T and TCR therapies experienced this acutely—they struggled to efficiently insert genetic material into T cells without damaging them, which reduced cell viability and therapeutic efficacy. The problem was measurable: delivery efficiency rates typically ranged from 20-40%, with significant cell death during the process. Existing alternatives like electroporation caused substantial cellular stress, while viral vectors raised safety concerns and manufacturing complexity. Early validation came when leading academic immunotherapy labs and contract manufacturers immediately recognized the µVS approach's potential. The microfluidic vortex shedding mechanism demonstrated superior delivery rates with minimal cell perturbation in preliminary experiments. Conversations with three major CAR-T developers revealed they would adopt a validated non-viral solution immediately, signaling strong market pull. These early conversations from potential customers—not theoretical interest—validated that Indee Labs had identified a genuine, acute pain point worth solving.